Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Blood (2014) 124 (21): 723.

https://doi.org/10.1182/blood.V124.21.723.723

Published: 2014

Journal Articles

The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma

Eileen M Boyle, MD, Annamaria Brioli, MD, Xavier Leleu, MD, PhD, Gareth J Morgan, MD PhD, Charlotte Pawlyn, MD, Faith E Davies, MD, John P Campbell, PhD, Mark T Drayson, MD PhD

Blood (2013) 122 (21): 1895.

https://doi.org/10.1182/blood.V122.21.1895.1895

Published: 2013

Journal Articles

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Annamaria Brioli, MD, Charlotte Pawlyn, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Samantha Marshall, Jindriska Lindsay, MD, Claire Chapman, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Michele Cavo, MD, Graham H Jackson, MD, Nigel Russel, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 2074.

https://doi.org/10.1182/blood.V122.21.2074.2074

Published: 2013

Journal Articles

A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort

Martin F. Kaiser, MD, Dil Begum, BSc, Paula Proszek, MSc, Nasrin Dahir, BSc, David Gonzalez de Castro, PhD, Charlotte Pawlyn, MD, Annamaria Brioli, MD, Suvi Savola, PhD, Walter Gregory, PhD, Roger G. Owen, MD, Graham H. Jackson, MD, Faith E Davies, MD, Brian A Walker, PhD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 3097.

https://doi.org/10.1182/blood.V122.21.3097.3097

Published: 2013

Journal Articles

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Charlotte Pawlyn, MD, Annamaria Brioli, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Jindriska Lindsay, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, Claire Chapman, MD, Roger G Owen, MD, Mark T Drayson, MD PhD, Nigel Russell, MD, Graham H Jackson, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 540.

https://doi.org/10.1182/blood.V122.21.540.540

Published: 2013

Journal Articles

Discovery Of Genome Wide Epigenetic Programming In t(4;14) Multiple Myeloma and In The Progression From Myeloma To Plasma Cell Leukemia Via Methyl Binding Domain Protein Capture and Sequencing

Martin F Kaiser, MD, Alexander Murison, PhD, Christopher P Wardell, PhD, David C Johnson, PhD, Charlotte Pawlyn, MD, Fabio Mirabella, PhD, Lorenzo Melchor, PhD, Kerry Fenwick, Iwanka Kozarewa, PhD, Faith E Davies, MD, Brian A Walker, PhD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 599.

https://doi.org/10.1182/blood.V122.21.599.599

Published: 2013

Journal Articles

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Charlotte Pawlyn, MD, Lorenzo Melchor, PhD, Eileen M Boyle, MD, Annamaria Brioli, MD, Martin F Kaiser, MD, Walter Gregory, PhD, Mark T Drayson, MD PhD, Graham Jackson, MD, Fiona M Ross, DPhil, J. Anthony Child, MD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2013) 122 (21): 529.

https://doi.org/10.1182/blood.V122.21.529.529

Published: 2013

Journal Articles

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Annamaria Brioli, MD, John P. Campbell, PhD, Martin F Kaiser, MD, Charlotte Pawlyn, MD, Graham H. Jackson, MD, Walter Gregory, PhD, Roger G. Owen, MD, J. Anthony Child, MD, Faith E. Davies, MD, Michele Cavo, MD, Mark T. Drayson, MD PhD, Gareth J. Morgan, MD PhD

Blood (2013) 122 (21): 752.

https://doi.org/10.1182/blood.V122.21.752.752

Published: 2013

Journal Articles

Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial

Charlotte Pawlyn, MD, Faith E. Davies, MD, Walter M Gregory, PhD, Alex J Szubert, MSc, Sue E Bell, DPhil, Jacqueline Ouzman, PhD, Mark T Drayson, MD, Roger G Owen, MD, Graham H Jackson, MD, Nigel H Russell, MD, Gareth J. Morgan, MD, PhD

Blood (2012) 120 (21): 335.

https://doi.org/10.1182/blood.V120.21.335.335

Published: 2012

Journal Articles

The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping

Annamaria Brioli, MD, Fiona M Ross, DPhil, Martin F Kaiser, MD, Charlotte Pawlyn, MD, Ping Wu, MBBS, MSc, Walter M Gregory, PhD, Roger G Owen, MD, Graham H Jackson, MD, Michele Cavo, MD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 199.

https://doi.org/10.1182/blood.V120.21.199.199

Published: 2012

Journal Articles

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

Nory Holle, Ping Wu, MBBS, MSc, Charlotte Pawlyn, MD, Radovan Saso, MD, MPhil, PhD, Jennifer G. Treleaven, MD, Michael Potter, MD PhD, Mark E Ethell, MD, Bronwen E. Shaw, MD PhD, Walter M Gregory, PhD, Sandra Croockewit, MD, Gareth J. Morgan, MD PhD, Faith E. Davies, MD

Blood (2012) 120 (21): 3125.

https://doi.org/10.1182/blood.V120.21.3125.3125

Published: 2012

NARROW

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Discovery Of Genome Wide Epigenetic Programming In t(4;14) Multiple Myeloma and In The Progression From Myeloma To Plasma Cell Leukemia Via Methyl Binding Domain Protein Capture and Sequencing

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial

The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only